Reading the tape
NASDAQ: BIOA
BioAge Labs, Inc.
Healthcare · Biotechnology
Market Cap
$611.48M
52w High
$24.00
52w Low
$3.67
P/E
-7.58
Volume
3.13K
Outstanding Shares
35.98M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 300.48%FCF (TTM): -58.7%
What changed
The stock rose 300.48% over the last year. Free cash flow declined 58.7% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -1,031.46%. A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases.
CEOKristen Fortney
SectorHealthcare
IndustryBiotechnology
Employees62
IPO dateSep 26, 2024
Valuation
Forward P/E—
EV/EBITDA-3.15
Enterprise value$292.06M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin99.23%
Operating margin-1,031.46%
ROE-29.63%▼34.64%vs FY2024
Analyst consensus
RatingBuy
Target price$45.00▲164.78%
2
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$0.64 · Revenue est $1.08M
View